Member Info for Fardistanthills

Fantastic news - the as hoped for very favourable safety profile and re the in tumour release mechanism - but also the not quite so anticipated move, seeking an MTD. And very much agree it is also about confriming the platform. The stand out for Avacta id that it has these platform chemistries. Above all fantastic news for cancer patients.

Well argued BV and in line with what I have beenwondering for some while. If 1a has shown the sort of promise some suspect then to unlock the potential of AVA6k the next stage of the trials could involve some innovative dosing regimens.

Shortly after early January?

Kenyan - "too academic for my Chemistry degree from years ago" Thank goodness I'm not alone - I'm not sure whether I've forgotten all my chemistry or whether chemistry has become ever more complex - 'cleverer' But I do get the gist so thanks for posting gadgie

Very good summary. An Avacta good new year everyone.

The market being all seeing/all knowing is a fallacy... correct! Patience is what counts:

The vision to see them, the courage to buy them and the patience to hold them - patience is the rarest of the three… Thomas Phelps: 100 to 1 in the Stock Market.

It was never my thinking that made the big money for me. It was my sitting - my sitting tight... Jesse Livermore

If you invest to get rich quickly you will probably only succeed in getting poor quickly... Warren Buffett.

Mind you it is not advice that I have found easy to take!

RMF Muckle, thanks for those interesting links - if all goes well as it seems it will, AVA6k and their whole prodrug platform will be launching into a very receptive environment.

Exactly - that's what having a platform is all about - the value is in the platform - use others have the skill set to produce. Out-licensing will be what Avacta do.

I hope there is no t/o - as a patient holder prepared to stay for the long term I reckon I would be much better rewarded if AVCT are able to negotiate one or more jvs and follow through exploiting all their other multiple opportunities. The level at which any near term offer for the therapeutcis side of Avacta is deemed acceptable will depend on what major holders / IIs are prepared to accept. I cannot believe any major pharma would overpay absent any sort of bidding process.

PL75... very well put

CH bitl - could the people that have been having the treatment be now cured/clear?? It is an interesting question - but might the clinicians be learning something from the survivorship of the earlier first/earlier cohorts?

Thanks - an interesting reference or two in this to Avact, e.g ...

We already have an established network of academic partners in numerous Universities and have had funding with industry eg Tecrea (Innovate feasability grant), Pfizer (CASE studentship), Fera (CASE studentship) and Avacta Life Sciences (CASE studentship, license agreement). Some of the Affimers generated in our laboratory for Avacta Life Science are available to purchase and we regularly screen targets for Avacta's industrial collaborators and clients. Some of our unpublished results have generated commercial interest and investment in the Affimer brand which recently helped Avacta fund raise for a therapeutic programme, some of which will be fed back into the academic projects at Leeds.

... as the King said to Liz

IFA / Gengis, indeed, need to be very wary re what's posted on here!

Chartmy 07:54 - It’s impossible for indications of progress not to be given on Thursday when AS meets with investors

Help please - I'm obviously not keeping up - when was a meeting with investors announced?

So RR, according to your logic / explanation, reply to hanoihank, the price will always go down?

I am just amazed that so many people are amazed. By the way, good post EGTP

I normally skim these sorts of posts, I'm more interested in information released as RNSs and posted by those rare few really knowlegeable folk on here. But I thought the comment from wyndrum that the original allocation was pathetic rather took the biscuit! AS has rightly said and I am sure most holders agree with him, especially those who have held AVCT for a while, that further dilution should ideally be avoided. To my mind it is very reassuring that AVCT are at a stage where significant dilution can now be avoided.

Affimers were what originally caught my eye when I came across Avacta some years ago. The focus since that 2017 video has shifted to LFTs and now to the potential of their pro-drug platform. But if eventually reached, the potential of Avacta's affimer technology platform could be equally mind blowing.

Does anyone know how much cash it will take to get AVA6000 to market

And is it not interesting that on the Science day they say they will be

"providing a full technical update to shareholders on the Affimer immunotherapy and pre|CISION chemotherapy programmes"

So "Affimers and pre|CISION"?